Granted Patent
B2
US 12,459,981 · App. 17/311,226 · Granted Nov 4, 2025
Primary NK CAR constructs and methods
Assignee:
ImmunityBio, Inc.
C07K14/55A61K40/15A61K40/31A61K40/421A61K40/4234A61K45/06C07K14/7051C07K14/70521C07K16/2827C12N5/0638C12N5/0646C12N15/85C07K2317/622C07K2317/732C07K2319/03C07K2319/33C12N2510/00C12N2830/001C12N2830/50C12N2840/203
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed herein are recombinant nucleic acids, comprising a 5′ untranslated (5′-UTR) sequence portion, a signal peptide sequence portion, a single chain antibody fragment sequence portion, a hinge region sequence portion, a transmembrane domain sequence portion, and one or more intracellular domain sequence portions. Also disclosed herein are modified natural killer (NK) cells comprising the recombinant nucleic acid described above. Further disclosed herein are methods of treating a tumor in a subject by administering the modified NK cells.
Claims (6)
1 . A recombinant nucleic acid, comprising:
a T7 promoter sequence portion, a 5′ untranslated (5′-UTR) sequence portion, a sequence portion encoding a signal peptide, a sequence portion encoding a single chain antibody fragment, a sequence portion encoding a hinge region, a sequence portion encoding a transmembrane domain, and a sequence portion encoding one or more intracellular domains; and
wherein the nucleic acid comprises any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4.
2 . The recombinant nucleic acid of claim 1 , wherein the hinge provides range of motion for the single chain antibody fragment, the transmembrane domain enables insertion of a transmembrane domain into a membrane, and/or the intracellular domain provides enhanced cytotoxic activity against tumor cells.
3 . The recombinant nucleic acid of claim 1 , wherein the recombinant nucleic acid is in a vector.
4 . The recombinant nucleic acid of claim 1 , further comprising a sequence portion encoding CD16a or ER-IL2.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 23, 2025
From: DUGGAL, ROHIT; PARVIZ, FERESHTEH
To: NANTKWEST, LLC
Reel/Frame 069981/0709 →
SECURITY INTEREST
Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
CHANGE OF NAME
Recorded Aug 19, 2021
From: NANTKWEST, INC.
To: IMMUNITYBIO, INC.
Reel/Frame 057246/0834 →
Continuity (1)
References Cited (59)
US 9745368B2
· Milone et al.
· 2017
[cited by applicant]
US 20040018536A1
· Yanagawa et al.
· 2004
[cited by applicant]
US 20040076622A1
· Studeny et al.
· 2004
[cited by applicant]
US 20160046729A1
· Schönfeld et al.
· 2016
[cited by applicant]
US 20160361360A1
· Chang et al.
· 2016
[cited by applicant]
US 20190336533A1
· Hwang et al.
· 2019
[cited by applicant]
US 20230272042A1
· Boissel
· 2023
[cited by examiner]
CA 3113962A1
· 2021
[cited by applicant]
CN 107073138A
· 2017
[cited by applicant]
CN 107708741A
· 2018
[cited by applicant]
CN 109219445A
· 2019
[cited by applicant]
CN 109419818A
· 2019
[cited by applicant]
JP 2002176987A
· 2002
[cited by applicant]
JP 2005531507A
· 2005
[cited by applicant]
JP 2016533769A
· 2016
[cited by applicant]
WO 2013033626A2
· 2013
[cited by applicant]
WO 2013040371A2
· 2013
[cited by applicant]
WO 2014099671A1
· 2014
[cited by applicant]
WO 2014145252A2
· 2014
[cited by applicant]
WO 2016201300A1
· 2016
[cited by applicant]
WO 2018013975A1
· 2018
[cited by applicant]
WO 2019082721A1
· 2019
[cited by applicant]
WO 2019101998A1
· 2019
[cited by applicant]
WO 2019178580A1
· 2019
[cited by applicant]
WO 2021107940A1
· 2021
[cited by applicant]
Vajdos FF et al. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. J Mol Biol. Jul. 5, 2002;320(2):415-28. doi: 10.1016/S0022-2836(02)00264-4…
[cited by examiner]
Brown M, et al. Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR 2: a means of minimizing B cell wastage from somatic hypermutation? J Immunol. May 1, 1996;156(9):3285-91. PMID: 8617951.…
[cited by examiner]
Extended European Search Report received for EP Patent Application Serial No. 19946247.4 dated Jul. 7, 2023, 7 pages.
[cited by applicant]
First Office Action received for KR Patent Application Serial No. 10-2021-7011005 dated Jul. 18, 2023, 11 pages.
[cited by applicant]
Notice of Allowance received for KR Patent Application Serial No. 10-2021-7011005 dated Jul. 18, 2023, 12 pages.
[cited by applicant]
Notice of Eligibility received for SG Patent Application Serial No. 11202103528V dated Jan. 16, 2024, 04 pages.
[cited by applicant]
Notice of Reason for Refusal received for JP Patent Application Serial No. 2021-520551 dated Oct. 13, 2023, 09 pages.
[cited by applicant]
Second Office Action received for CN Patent Application Serial No. 201980067946.0 dated Oct. 19, 2023, 09 pages.
[cited by applicant]
Search Report and Written Opinion received for Singapore Patent Application Serial No. 11202103528V dated May 10, 2022, 8 pages.
[cited by applicant]
International Preliminary Report on Patentability received for PCT Application Serial No. PCT/US2019/063454 dated Jun. 9, 2022, 8 pages.
[cited by applicant]
International Search Report and Written Opinion received for International PCT Application Serial No. PCT/US2019/063454 dated Aug. 14, 2020, 11 pages.
[cited by applicant]
Examination Report No. 1 received for Australian Patent Application Serial No. 2019468311 dated Sep. 23, 2022, 7 pages.
[cited by applicant]
Kruschinski et al., “Engineering Antigen-Specific Primary Human NK Cells against HER-2 Positive Carcinomas”, Proceedings of the National Academy of Sciences of the United States of America, vol. 105, No. 45, 2008, pp. 1…
[cited by applicant]
Notice of Reasons for Refusal received for Japanese Patent Application Serial No. 2021-520551 dated Mar. 3, 2023, 12 pages. (Including English Translation).
[cited by applicant]
First Office Action received for Chinese Patent Application Serial No. 201980067946.0 dated Mar. 30, 2023, 34 pages. (Including English Translation).
[cited by applicant]
Notice of Acceptance received for Australian Patent Application Serial No. 2019468311 dated May 9, 2023, 3 pages.
[cited by applicant]
Notice of Acceptance received for Canadian Patent Application Serial No. 3,113,962 dated May 11, 2023, 1 page.
[cited by applicant]
Office Action received for Canadian Patent Application Serial No. 3,113,962 dated Mar. 31, 2022, 5 pages.
[cited by applicant]
Office Action issued for KR Application No. 10-2024-7019177 dated Aug. 26, 2024, 11 Pages (including English Translation).
[cited by applicant]
Notice of Allowance received for KR Application No. 10-2024-7019177 dated Dec. 31, 2024, 12 Pages (including English Translation).
[cited by applicant]
Notice of Allowance received for KR Application No. 10-2024-7008007 dated Mar. 19, 2024, 12 Pages (including English Translation).
[cited by applicant]
Office Action received for Japanese Patent Application Serial No. 2021-520551 dated Jun. 28, 2024, 06 pages (Including English Translation).
[cited by applicant]
Notice of Allowance received for Japanese Patent Application Serial No. 2021-520551 dated Dec. 17, 2024, 05 pages (Including English Translation).
[cited by applicant]
Notice of Allowance received for Chinese Patent Application Serial No. 201980067946.0 dated Feb. 1, 2024, 04 pages. (Including English Translation).
[cited by applicant]
Examination Report No. 1 for Australian Application No. 2023204206 dated Jan. 15, 2025. 2 pages.
[cited by applicant]
Extended European Search Report dated Feb. 21, 2025.
[cited by applicant]
Examinnation Report for IL Patent Application No. 282319 dated: May 21, 2025, 16 pages (including English Translation).
[cited by applicant]